甲状腺未分化癌的分子机制研究

doi:10.6040/j.issn.1673-3770.1.2020.029

摘要/Abstract

摘要： 甲状腺未分化癌(ATC)是一种罕见的侵袭型甲状腺恶性肿瘤,进展迅速、预后差,目前缺乏疗效显著的治疗方法和早期诊断方案。有学者研究显示,ATC预后不良是由于肿瘤早期突变以及肿瘤侵袭性生长,因此针对ATC发病机制的驱动突变及靶向药物的研究成为新方向。在ATC中涉及与肿瘤进展相关的不同分子途径,并且有学者探讨实施作用于这些分子途径的新疗法,以改善患者生活质量。对ATC分子结构特征的研究成果,为新的靶向治疗带来希望,新的分子机制将有助于发现更多潜在的治疗靶点,综述近年来ATC的分子机制研究概况。

关键词: 甲状腺未分化癌, 侵袭型恶性肿瘤, 分子机制, 基因, 靶向治疗

Abstract: Anaplastic thyroid cancer(ATC)is a rare invasive thyroid tumor associated with rapid progression and poor prognosis. Currently, there is no effective treatment or early diagnosis. Some scholars have shown that the poor prognosis of ATC is due to the early mutation and invasive growth of the tumor; consequently, new directions in research involve the driving mutation of the pathogenesis of ATC and targeted drug therapies. Different molecular pathways related to tumor progression are involved in ATC. Some scholars have explored the implementation of new therapies that act on these molecular pathways to improve patients' quality of life. The research results on the molecular structural characteristics of ATC bring hope for new targeted therapies. The new molecular mechanisms will help us discover more potential therapeutic targets. We have reviewed the recent research on the molecular mechanisms of ATC.

Key words: Anaplastic thyroid carcinoma, Invasive malignancy, Molecular mechanism, Genes, Targeted therapy

中图分类号:

R739.91

青晓艳,徐义全,李超. 甲状腺未分化癌的分子机制研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 26-31.

QING Xiaoyan,XU Yiquan,LI Chao. Advances in molecular mechanisms of anaplastic thyroid cancer[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 26-31.

参考文献

[1] 宋晓宇, 宋西成. 缺氧诱导因子-1α在甲状腺癌中的调节机制[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 136-138, 148. doi:10.6040/j.issn.1673-3770.0.2018.317. SONG Xiaoyu, SONG Xicheng. Research progress on the regulation of HIF-1α expression in thyroid carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 136-138, 148. doi:10.6040/j.issn.1673-3770.0.2018.317.
[2] 中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1): 1-15. doi:10.3877/cma.j.issn.1674-0793.2019.01.001.
[3] Zheng JX, Cheng X, Xu SC, et al. Diallyl trisulfide induces G2/M cell-cycle arrest and apoptosis in anaplastic thyroid carcinoma 8505C cells[J]. Food Funct, 2019, 10(11): 7253-7261. doi:10.1039/c9fo00646j.
[4] Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer[J]. Horm EtMetab, 2020,10. doi:10.1055/a-1089-7870.
[5] Hugen N, Sloot YJE, Netea-Maier RT, et al. Divergent metastatic patterns between subtypes of thyroid carcinoma results from the nationwide Dutch pathology registry[J]. J Clin Endocrinol Metab, 2020, 105(3): dgz078. doi:10.1210/clinem/dgz078.
[6] Jiao C, Li L, Zhang P, et al. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway[J]. Cell Death Differ, 2020, 27(2): 497-508. doi:10.1038/s41418-019-0367-9.
[7] Ma YH, Cang SD, Li GQ, et al. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression[J]. J Cell Physiol, 2019, 234(12): 22260-22271. doi:10.1002/jcp.28793.
[8] Kohler H, Latteyer S, HönesGS, et al. Increased anaplastic lymphoma kinase activity induces a poorly differentiated thyroid carcinoma in mice[J]. Thyroid, 2019, 29(10): 1438-1446. doi:10.1089/thy.2018.0526.
[9] Wang Q, Sui GQ, Wu XL, et al. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics[J]. Acta Biomater, 2020, 102: 367-383. doi:10.1016/j.actbio.2019.11.043.
[10] Weber F, Junger H, Werner JM, et al. Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas[J]. Cancer Med, 2019, 8(16): 7065-7073. doi:10.1002/cam4.2573.
[11] Schürch CM, Roelli MA, Forster S, et al. Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy[J]. Thyroid, 2019, 29(7): 979-992. doi:10.1089/thy.2018.0555.
[12] Ferrari SM, Elia G, Ragusa F, et al. Novel treatments for anaplastic thyroid carcinoma[J]. Gland Surg, 2020, 9(Suppl 1): S28-S42. doi:10.21037/gs.2019.10.18.
[13] Hao Z, Wang P. Lenvatinib in Management of Solid Tumors[J]. Oncologist,2020,25(2):e302-e310. doi: 10.1634/theoncologist.2019-0407.
[14] Stenman A, Hellgren LS, Jatta K, et al. Metastatic anaplastic thyroid carcinoma in complete remission: morphological, molecular, and clinical work-up of a rare case[J]. Endocr Pathol, 2020, 31(1): 77-83. doi:10.1007/s12022-020-09606-5.
[15] Paulsson JO, Backman S, Wang N, et al. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation[J]. J Pathol, 2020, 250(2): 183-194. doi:10.1002/path.5359.
[16] Calabrese G, Dolcimascolo A, Caruso G, et al. MiR-19a is involved in progression and malignancy of anaplastic thyroid cancer cells[J]. Onco Targets Ther, 2019, 12: 9571-9583. doi:10.2147/OTT.S221733.
[17] Pellecchia S, Sepe R, Decaussin-Petrucci M, et al. The long non-coding RNA Prader willi/angelman region RNA5(PAR5)is downregulated in anaplastic thyroid carcinomas where it Acts as a tumor suppressor by reducing EZH2 activity[J]. Cancers(Basel), 2020, 12(1): E235. doi:10.3390/cancers12010235.
[18] Credendino SC, Bellone ML, Lewin N, et al. A Cernacircuitry involving the long noncoding RNA Klhl14-AS, Pax8, and Bcl2 drives thyroid carcinogenesis[J]. Cancer Res, 2019, 79(22): 5746-5757. doi:10.1158/0008-5472.CAN-19-0039.
[19] Wächter S, Vorländer C, Schabram J, et al. Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival[J]. Eur Arch Otorhinolaryngol, 2020, 277(5): 1507-1514. doi:10.1007/s00405-020-05853-8.
[20] Nikitski AV, Rominski SL, Condello V, et al. Mouse model of thyroid cancer progression and dedifferentiation driven by STRN-ALK expression and loss of p53: evidence for the existence of two types of poorly differentiated carcinoma[J]. Thyroid, 2019, 29(10): 1425-1437. doi:10.1089/thy.2019.0284.
[21] Lin B, Ma HQ, Ma MG, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis[J]. Am J Transl Res, 2019, 11(9): 5888-5896.
[22] Yan P, Su ZJ, Zhang ZH, et al. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR?9?5p and regulating SPAG9 expression[J]. Int J Oncol, 2019, 55(5): 988-1002. doi:10.3892/ijo.2019.4868.
[23] Revilla G, Pons MP, Baila-Rueda L, et al. Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness[J]. Sci Rep, 2019, 9(1): 10260. doi:10.1038/s41598-019-46727-2.
[24] Zhong ZM, Chen X, Qi X, et al. Adaptor protein LNK promotes anaplastic thyroid carcinoma cell growth via 14-3-3 ε/γ binding[J]. Cancer Cell Int, 2020, 20: 11. doi:10.1186/s12935-019-1090-9.
[25] Pereira M, Williams VL, Hallanger Johnson J, et al. Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations[J]. Thyroid, 2020,3. doi:10.1089/thy.2019.0415.
[26] Minna E, Brich S, Todoerti K, et al. Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma[J]. Cancers(Basel), 2020, 12(1): E112. doi:10.3390/cancers12010112.
[27] Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(12): 1429-1440. doi:10.6004/jnccn.2018.0089.
[28] Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective[J]. Mol Cancer, 2018, 17(1): 154. doi:10.1186/s12943-018-0903-0.
[29] Mirian C, Grnhj C, Jensen DH, et al. Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980-2014[J]. Cancer Epidemiol, 2018, 55: 81-87. doi:10.1016/j.canep.2018.05.009.
[30] Gunda V, Gigliotti B, Ndishabandi D, et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J]. Br J Cancer, 2018, 119(10): 1223-1232. doi:10.1038/s41416-018-0296-2.
[31] Ljubas J, Ovesen T, Rusan M. A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer[J]. Cancers(Basel), 2019, 11(7): E943. doi:10.3390/cancers11070943.

相关文章 15

[1]	王敏,刘皓,姜露涵,谭立约,李文,付小龙. AAV-ie-Tnfaip8l2的包装及其对Tnfaip8l2^-/-小鼠听觉功能的改善效果[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 7-15.
[2]	盘琳琳,万佳明,李越,何龙. 自噬相关LncRNA是头颈部鳞状细胞癌的预后指标[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 97-107.
[3]	李洁,苏维娜,林倩,张奇舒,侯成,杨振娇,相丽丽. 两例耳聋病例中MARVELD2基因变异的遗传学分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 128-134.
[4]	张丽霞,李琳. 基于GEO数据库筛选年龄相关性听力损失关键基因的分析研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 104-114.
[5]	王博深,冷辉,孙海波. 梅尼埃病与前庭性偏头痛共表达基因特征及天麻素的分子对接预测[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 29-40.
[6]	张韵秋,任秀敏,徐鸥,董金辉,王建星. 奥马珠单抗靶向治疗慢性鼻窦炎伴鼻息肉的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 136-140.
[7]	王玲,黎明,应方微,王玉,温文,姚晓明. 微孢子虫感染导致角膜穿孔1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 95-99.
[8]	倪荣生,沈晓辉,高下. 基质金属蛋白酶及其抑制剂在喉鳞癌中的基因表达谱及临床病理特征相关性分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 55-61.
[9]	刘若武,张晗. Leber遗传性视神经病变的基因治疗进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 154-158.
[10]	艾朝晖, 张杰. 色素失禁症相关性眼病诊疗研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 166-174.
[11]	卢松,夏逸帆,李子晔,魏菁. 无视网膜脱离的儿童Stickler综合征1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 97-101.
[12]	张瑾,亓志玲,王少华,赵玉凤,马旭,吴允刚. 神经纤维瘤病Ⅰ型新致病基因突变1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 73-78.
[13]	李为,赵毅,葛玥铭,付洪涛,王进东,张晓龙,董洁,程钰翔. 新生儿常见耳聋基因突变热点及对听力的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 1-8.
[14]	张永红,张辉,王彩华,杨欣欣,吴允刚,赵玉凤,庞太忠,李晓瑜. 基于TCGA数据库构建喉鳞状细胞癌免疫相关基因预后模型及筛选靶向分子药物[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 54-62.
[15]	周一静,邹建银,易红良,吴红敏. TGFBI在头颈部鳞状细胞癌中的表达及其临床意义[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 85-95.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed